Investment
Features
FeesSafety
Academy
More
Pluang+

Compare ProShares Ultra Bloomberg Natural Gas ETF (BOIL) vs Heron Therapeutics Inc (HRTX) Price & Performance

ProShares Ultra Bloomberg Natural Gas ETFTrade
Heron Therapeutics IncTrade

Price performance (Past 24H)

Key statistics

ProShares Ultra Bloomberg Natural Gas ETF vs Heron Therapeutics Inc — how do they compare? ProShares Ultra Bloomberg Natural Gas ETF trades at $22.45, while Heron Therapeutics Inc trades at $0.42 (market cap $82.52M). Which is the better fit depends on your goals.

BOILHRTX
Sector
Leveraged / InverseHealth
52-Week High
$98.62$2.04
52-Week Low
$21.86$0.39
Market Cap
$82.52M
Enterprise Value
$180.42M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

ProShares Ultra Bloomberg Natural Gas ETF

BOIL trades at $21.86, down 3.62% on the day, with technical indicators showing a bearish trend despite oversold RSI readings. The stock recently underwent a 1:2 split on May 28, 2026. Natural gas market volatility dominates sentiment, with futures fluctuating based on weather forecasts and LNG demand. Fundamental data remains unavailable, highlighting the speculative nature of this leveraged ETF.

The outlook remains highly speculative given BOIL's leveraged structure and dependence on natural gas price movements. Key risks include contango erosion and weather-driven volatility. Investment opportunity exists for tactical traders betting on natural gas price surges, but long-term value erosion remains a significant concern for buy-and-hold investors.

Heron Therapeutics Inc

HRTX trades at $0.42 with a slight 0.6% daily gain, but technical indicators show a bearish trend with moving averages signaling sell pressure. The company reported Q1 2026 revenue of $151M with a net loss of $31M, continuing negative profitability trends. Recent news highlights patent litigation developments and management reaffirming full-year guidance despite quarterly misses.

While analyst consensus remains overwhelmingly bullish (95% buy ratings), fundamental challenges persist with negative earnings and cash flow. Investment opportunity exists if the company can achieve profitability turnaround, but risks include ongoing operational losses, competitive pressures in biotechnology, and patent litigation uncertainties.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About ProShares Ultra Bloomberg Natural Gas ETF

BOIL is a leveraged ETF that seeks to provide two times (2x) the daily performance of the Bloomberg Natural Gas Subindex. It uses futures contracts to offer magnified exposure to natural gas price movements.

Read more on BOIL

About Heron Therapeutics Inc

Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.

Read more on HRTX